Date: 2016-10-06
Type of information: Opening of new premises
Compound: M Lab™ Collaboration Center in Incheon
Company: Merck KGaA (Germany)
Therapeutic area: Technology - Services
Type agreement: opening of new premises
Action mechanism:
Disease:
Details:
- • On October 6, 2016, Merck KGaA announced the opening of an M Lab™ Collaboration Center in the Songdo district of Incheon, Korea. The center provides biopharmaceutical manufacturers with a shared, exploratory environment where they can closely collaborate with Merck KGaA scientists and engineers to solve their toughest challenges and accelerate development and production of new therapies. The new M Lab™ Collaboration Center replaces a smaller facility in Seoul and will better suit the needs of Korea’s growing biopharmaceutical market. The new center will include a simulated manufacturing environment and offer full end-to-end process development support. In addition, education on best practices and new approaches to develop, optimize and scale-up processes and simplify global technology transfer will be available to customers. With 1,865 square meters of space and more than ten highly trained scientists and engineers, the M Lab™ Collaboration Center will serve local biopharma manufacturers, spanning the spectrum from multinational organizations like Samsung Biologics to emerging companies developing biologics to treat rare diseases or different types of cancer.
- The new M Lab™ Collaboration Center in Incheon is one of nine such centers around the world. Each center allows pharmaceutical manufacturers to explore new ways to increase productivity, improve processes and mitigate risks by giving them access to a world-class team of experts. Customers have access to sizing and simulation tools and methodologies as well as analytical and modeling support. Formal bioprocessing educational courses are also available, including traditional classroom-style training and interactive, hands-on sessions.
Financial terms:
Latest news:
Is general: Yes
